ANI Pharmaceuticals
ANIP
71.93
+0.41
+0.57%
ANI Pharmaceuticals
US · ANIP
#2919 by market cap
Listed 1970
71.93
+0.41
+0.57%
Live - 5344 symbols - heartbeat 404s ago
· 2026-10-08 04:21
Pre-market
71.92
-0.01%
After-hours
72.15
+0.31%
- Market cap
- 1.65B
- P/E (TTM)i
- 15.67
- P/Bi
- 2.77
- EPSi
- 3.32
- Div yieldi
- 0.00%
- 52W posi
- 9%
Reader sentiment
Are you bullish or bearish on ANIP?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 7 analysts
Buy
Avg price target
104.86 +45.8%
Price target rangecurrent 71.93
Low85.00
Avg104.86
High121.00
Buy 71%
Hold 29%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-09-23 | Oppenheimer | -- | HOLD | 85.00 |
| 2026-09-21 | H.C. Wainwright | -- | BUY | 121.00 |
| 2026-09-09 | Leerink Partners | -- | BUY | 104.00 |
| 2026-08-25 | Barclays | -- | BUY | 100.00 |
| 2026-08-11 | H.C. Wainwright | -- | BUY | 121.00 |
| 2026-08-10 | CCORF | -- | HOLD | 90.00 |
| 2026-08-10 | J.P. Morgan | -- | BUY | 115.00 |
| 2026-08-07 | Guggenheim | -- | BUY | 119.00 |
| 2026-08-05 | Barclays | -- | BUY | 100.00 |
| 2026-07-17 | CCORF | -- | HOLD | 91.00 |
| 2026-07-16 | CCORF | -- | HOLD | 91.00 |
| 2026-07-14 | Guggenheim | -- | BUY | 124.00 |
| 2026-07-13 | H.C. Wainwright | -- | BUY | 121.00 |
| 2026-07-09 | Guggenheim | -- | BUY | 124.00 |
| 2026-05-20 | Barclays | -- | BUY | 100.00 |
| 2026-05-11 | Truist Financial | -- | HOLD | -- |
| 2026-05-10 | Guggenheim | -- | BUY | 124.00 |
| 2026-05-08 | H.C. Wainwright | -- | BUY | 121.00 |
| 2026-04-23 | Piper Sandler | -- | BUY | 111.00 |
| 2026-04-16 | Guggenheim | -- | BUY | 124.00 |
| 2026-03-25 | Jefferies | -- | BUY | 120.00 |
| 2026-03-19 | Barclays | -- | BUY | 100.00 |
| 2026-03-16 | Guggenheim | -- | BUY | 124.00 |
| 2026-03-02 | Truist Financial | -- | HOLD | -- |
| 2026-03-01 | Guggenheim | -- | BUY | 124.00 |
Quant vs Street three independent views, side by side
Momentum strategy signal
Sell
Analyst consensus
Buy
Signals diverge - worth digging into why.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q2 | 2026-08-07 | -- | ±9.98% | -5.30% (in line) |
| 2026/Q1 | 2026-05-08 | -- | ±8.03% | -2.44% (in line) |
| 2025/Q4 | 2026-02-27 | -- | ±12.21% | -4.21% (in line) |
| 2025/Q3 | 2025-11-07 | -- | ±8.17% | +0.22% (in line) |
| 2025/Q2 | 2025-08-08 | -- | ±12.06% | +18.07% (beat) |
| 2025/Q1 | 2025-05-09 | -- | ±12.57% | -7.31% (in line) |
| 2024/Q4 | 2025-02-28 | -- | ±15.48% | +13.39% (in line) |
| 2024/Q3 | 2024-11-08 | -- | ±10.99% | +5.24% (in line) |
| 2024/Q2 | 2024-08-06 | -- | ±11.66% | +6.98% (in line) |
| 2024/Q1 | 2024-05-10 | -- | ±7.89% | +3.29% (in line) |
| 2023/Q4 | 2024-02-29 | -- | ±10.51% | +12.26% (beat) |
| 2023/Q3 | 2023-11-08 | -- | ±12.35% | -14.64% (beat) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-08 04:21:51 · For reference only, not investment advice and not tailored to your situation.